Solengepras Meets Phase III Parkinson’s Endpoint
Cerevance reported that once-daily solengepras met the 12-week primary endpoint in Phase III ARISE, reducing daily OFF time versus placebo in levodopa-treated Parkinson’s disease. The result validates the trial’s non-dopaminergic GPR6 strategy at the…
